Skip to main content
OpenTrials
Completed

NCT Number: NCT03988387

IPREP Study #2: Evaluating Enhanced PrEP Packages for Young Female Sex Workers in Kisumu, Kenya

This is an open-label randomized controlled trial (n=200) in which HIV-negative young female sex workers (FSW) will be randomized to receive oral PrEP combined with specific behavioral and structural adherence interventions, either: (1) Intensive Peer Support (PS) or (2) Reminders and Resource Transfer (RRT).Respondent-driven sampling (RDS) will be used to recruit FSW as potential study participants.The study adherence interventions will be delivered over the first 12-month period in conjunction with PrEP. Thereafter, the study-specific adherence interventions will be withdrawn and PrEP continued for an additional 12 months with standard support as per national guidelines. Trial participants will be followed for a total of 24 months and attend 11 study visits over this period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Age range

18 year–24 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Tuungane Centre

Kisumu, Kenya

About this study

The overall aim of the proposed study is to compare the effectiveness, feasibility and acceptability of two adherence support interventions, peer support (PS) and reminders plus resource transfer (RRT), in combination with daily oral pre-exposure prophylaxis (PrEP) to optimize PrEP adherence among young in Kisumu, Kenya. Pre-exposure prophylaxis (PrEP) is a promising biomedical HIV prevention intervention. Findings from placebo-controlled efficacy trials highlight the need for adherence support to achieve PrEP efficacy and public health impact.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Report no previous diagnosis of HIV infection
  • Report being a cisgender female or transgender female
  • Report being between 18-24 years of age
  • Report living or working in study area
  • Report intention to stay in study area for 24 months
  • Report exchange sex with men for goods, money, favors or other services in past 3 months
  • Report no previous or recent (within the last 3 months) PrEP use
  • Able to complete study procedures in English, Kiswahili or Dholuo
  • Willingness to be randomized and adhere to study interventions according to eligibility, including PrEP

Exclusion criteria

  • Ineligible for PrEP according to Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya - 2018 Edition (National AIDS and STI Control Program, 2018)
  • Unable to provide informed consent for study procedures
  • Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the principle investigators, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  • Reports plan to leave area in the next 24 months

Treatment and study plan

Peer Support (PS)

Behavioral

Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.

Reminder and Resource Transfer (RRT)

Behavioral

Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is "Remember to look after yourself today, See you tomorrow." Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points.

daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]

Drug

All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF] for the first month of enrollment.

Primary outcomes

  1. PrEP Adherence between PS and RRT arms

    Time frame: 12 months

    Proportion of participants with ARV in plasma at 12-month visit

Secondary outcomes

  1. PrEP Adherence between PS and RRT arms, any visit

    Time frame: At all visits

    Proportion of participants with detectable ARV in plasma at any visit

  2. PrEP Adherence between PS and RRT arms, self-report

    Time frame: At all visits

    Proportion who report > 90% adherence by self-report

  3. PrEP adherence across PS and RRT arms

    Time frame: 18 and 24 months

    Proportion of participants with ARV in plasma at 18- and 24- month visits

  4. HIV risk behavior during PrEP use, propensity score

    Time frame: Baseline, 6, 12, 18, and 24 months

    Comparison of sexual risk propensity score

  5. HIV risk behavior during PrEP use, unprotected sex

    Time frame: Baseline, 6, 12, 18, and 24 months

    Proportions of participants reporting unprotected vaginal or anal sex in the prior 30 days

  6. Feasibility of PS and RRT interventions, intervention delivery

    Time frame: 24 months

    Proportion of expected intervention sessions delivered

  7. Feasibility of PS and RRT interventions, study visit retention

    Time frame: 24 months

    Proportion of participants retained at each study visit

  8. Completion of study visits between PS and RRT

    Time frame: 12, 18 and 24 months

    Proportion who completed scheduled PrEP study visits in PS and RRT arms at 18 and 24 months compared to proportion who completed these study visits at 12 months

  9. Scaled perception of PrEP, PS and RRT

    Time frame: 24 months

    Scaled perceptions of satisfaction with and utility of PS and RRT intervention components, PrEP, and clinical care

  10. Safety of PrEP including social harms

    Time frame: 24 months

    Discontinuation rates of PrEP due to an AE or drug toxicity and occurrence of social harms

  11. Discontinuation of PrEP

    Time frame: 24 months

    Discontinuation rates of PrEP due to situational changes, dislike of PrEP

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • Impact Research & Development Organization
  • National Institute of Mental Health (NIMH)

Registry information

Official study title

IPrEP, Study #2: Evaluating the Effectiveness, Feasibility and Acceptability of Enhanced Pre-exposure Prophylaxis (PrEP) Packages for Young Female Sex Workers in Kisumu, Kenya

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jun 17, 2019
Registry last updated
Sep 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.